Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Purchased by Wellington Management Group LLP

Wellington Management Group LLP increased its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 101.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 15,190,024 shares of the biopharmaceutical company’s stock after purchasing an additional 7,666,335 shares during the period. Wellington Management Group LLP owned 5.14% of Amicus Therapeutics worth $215,546,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of the stock. American International Group Inc. raised its position in shares of Amicus Therapeutics by 0.9% during the 4th quarter. American International Group Inc. now owns 141,249 shares of the biopharmaceutical company’s stock worth $2,004,000 after purchasing an additional 1,298 shares during the last quarter. Teachers Retirement System of The State of Kentucky acquired a new position in shares of Amicus Therapeutics during the 4th quarter worth approximately $1,178,000. Perceptive Advisors LLC raised its position in shares of Amicus Therapeutics by 1.3% during the 4th quarter. Perceptive Advisors LLC now owns 28,057,456 shares of the biopharmaceutical company’s stock worth $398,135,000 after purchasing an additional 364,539 shares during the last quarter. Old Well Partners LLC acquired a new position in shares of Amicus Therapeutics during the 4th quarter worth approximately $180,000. Finally, Great Point Partners LLC raised its position in shares of Amicus Therapeutics by 49.4% during the 4th quarter. Great Point Partners LLC now owns 1,280,500 shares of the biopharmaceutical company’s stock worth $18,170,000 after purchasing an additional 423,500 shares during the last quarter.

Amicus Therapeutics Stock Down 2.7 %

Shares of NASDAQ FOLD opened at $9.77 on Wednesday. Amicus Therapeutics, Inc. has a 52-week low of $9.02 and a 52-week high of $14.57. The firm has a fifty day moving average of $10.12 and a 200-day moving average of $11.78. The stock has a market capitalization of $2.89 billion, a PE ratio of -19.94 and a beta of 0.74. The company has a quick ratio of 2.61, a current ratio of 3.03 and a debt-to-equity ratio of 2.97.

Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.04. The company had revenue of $110.40 million during the quarter, compared to analysts’ expectations of $111.19 million. Amicus Therapeutics had a negative net margin of 34.73% and a negative return on equity of 77.08%. The business’s quarterly revenue was up 27.9% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.18) EPS. On average, analysts anticipate that Amicus Therapeutics, Inc. will post -0.12 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. JPMorgan Chase & Co. lowered their target price on shares of Amicus Therapeutics from $21.00 to $19.00 and set an “overweight” rating for the company in a research note on Monday, March 18th. Wells Fargo & Company assumed coverage on shares of Amicus Therapeutics in a research note on Thursday, May 30th. They issued an “overweight” rating and a $18.00 target price for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $22.00 target price on shares of Amicus Therapeutics in a research note on Thursday, February 29th. Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a research note on Friday, May 10th. Finally, Morgan Stanley lowered their target price on shares of Amicus Therapeutics from $20.00 to $19.00 and set an “overweight” rating for the company in a research note on Friday, May 10th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Amicus Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $17.57.

Insider Activity at Amicus Therapeutics

In related news, CEO Bradley L. Campbell sold 7,500 shares of Amicus Therapeutics stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $10.07, for a total transaction of $75,525.00. Following the transaction, the chief executive officer now owns 886,654 shares in the company, valued at approximately $8,928,605.78. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 2.20% of the company’s stock.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.